Megan S Lim

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
    Lindsay A Schmidt
    Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:121-6. 2009
  2. pmc Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
    David R Abbott
    Department of Pathology, University of Michigan Medical School, M5242 Medical Science 1, 1301 Catherine, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:113-9. 2009
  3. doi request reprint A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders
    Thirunavukkarasu Velusamy
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
    Blood 124:3768-71. 2014
  4. pmc Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome
    Mark J Kiel
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Commun 6:8470. 2015
  5. pmc Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
    Delphine Rolland
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
    Am J Pathol 184:1331-42. 2014
  6. doi request reprint Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays
    Noah A Brown
    Molecular Diagnostics Laboratory, Department of Pathology, University of Michigan Health System Swift Biosciences, Ann Arbor, MI
    Appl Immunohistochem Mol Morphol 23:590-600. 2015
  7. doi request reprint Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma
    Zilin Nie
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Commun 6:5908. 2015
  8. pmc Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
    Mark J Kiel
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
    Blood 124:1460-72. 2014
  9. doi request reprint High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis
    Noah A Brown
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI and
    Blood 124:1655-8. 2014
  10. pmc High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma
    Aaron M Udager
    Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan
    Cancer Res 75:2600-6. 2015

Collaborators

  • Alexey I Nesvizhskii
  • Michael J MacCoss
  • Damian Fermin
  • Kojo S J Elenitoba-Johnson
  • Noah A Brown
  • Bryan L Betz
  • Mark J Kiel
  • Delphine Rolland
  • Nathanael G Bailey
  • Thirunavukkarasu Velusamy
  • Roberto N Miranda
  • L Jeffrey Medeiros
  • Anagh A Sahasrabuddhe
  • Zilin Nie
  • Aaron M Udager
  • Delphine C M Rolland
  • Helmut C Weigelin
  • Fuzon Chung
  • Thomas Wolfe
  • Venkatesha Basrur
  • Kevin P Conlon
  • Jennifer M Hummel
  • David R Abbott
  • Lindsay A Schmidt
  • Steven L Kunkel
  • Ming Qing Du
  • Matthew Schaller
  • Jonathan B McHugh
  • Cory M Hogaboam
  • Peter C Lucas
  • John C Byrd
  • Nathanael Bailey
  • Kathleen E DuRoss
  • Julie Laliberté
  • Pierluigi Porcu
  • David W Bahler
  • Thomas E Carey
  • Linda M McAllister-Lucas
  • Mario A Hermsen
  • Lawrence J Marentette
  • Carlos Murga-Zamalloa
  • Alexandra C Hristov
  • Lili Zhao
  • Ryan A Wilcox
  • Catherine A Dixon
  • Jun Z Li
  • Yoon K Jeon
  • Bo Li
  • Alexandra Schrader
  • Larissa V Furtado
  • Kedar V Inamdar
  • Ayse B Ozel
  • Kevin Conlon
  • Marco Herling
  • David R Czuchlewski
  • Diane Roulston
  • Jennifer K Sanks
  • Lauren B Smith
  • Mihaela D Chiselite
  • M Carmen Frias Kletecka
  • Robert T Abbott
  • G Chris Fillmore
  • Stephen D Jenson

Detail Information

Publications15

  1. pmc T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
    Lindsay A Schmidt
    Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:121-6. 2009
    ..The spectrum of lymphoproliferative disorders associated with infliximab and the potential mechanisms by which they occur are discussed...
  2. pmc Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
    David R Abbott
    Department of Pathology, University of Michigan Medical School, M5242 Medical Science 1, 1301 Catherine, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:113-9. 2009
    ..Our findings further elucidate the cellular mechanisms accompanying Bcl-2 inhibition and demonstrate the potential of Bcl-2 inhibitors as therapeutic agents for the treatment of non-Hodgkin lymphomas...
  3. doi request reprint A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders
    Thirunavukkarasu Velusamy
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
    Blood 124:3768-71. 2014
    ..This is the first report of recurrent translocations involving TYK2, and it highlights the novel therapeutic opportunities in the treatment of CD30-positive LPDs with TYK2 translocations. ..
  4. pmc Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome
    Mark J Kiel
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Commun 6:8470. 2015
    ..Functional studies reveal sensitivity of JAK1-mutated primary SS cells to JAK inhibitor treatment. These results highlight the complex genomic landscape of SS and a role for inhibition of JAK/STAT pathways for the treatment of SS. ..
  5. pmc Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
    Delphine Rolland
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
    Am J Pathol 184:1331-42. 2014
    ..Overall, our study revealed the utility of unbiased phosphoproteome interrogation in characterizing signaling networks that may provide insights into pathogenesis mechanisms in B-cell lymphomas. ..
  6. doi request reprint Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays
    Noah A Brown
    Molecular Diagnostics Laboratory, Department of Pathology, University of Michigan Health System Swift Biosciences, Ann Arbor, MI
    Appl Immunohistochem Mol Morphol 23:590-600. 2015
    ..Two allele-specific PCR assays performed well in both frozen and FFPE bone marrow aspirates, although detection in FFPE tissue required 5% or more involvement. ..
  7. doi request reprint Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma
    Zilin Nie
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Commun 6:5908. 2015
    ..Our studies reveal a novel paracaspase-mediated oncogenic gain-of-function mechanism in the pathogenesis of MALT lymphoma. ..
  8. pmc Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
    Mark J Kiel
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
    Blood 124:1460-72. 2014
    ..These findings offer opportunities for novel targeted therapies in this aggressive leukemia...
  9. doi request reprint High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis
    Noah A Brown
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI and
    Blood 124:1655-8. 2014
    ..The mutually exclusive nature of MAP2K1 and BRAF mutations implicates a critical role of oncogenic MAPK signaling in LCH. This finding may also have implications in the use of BRAF and MEK inhibitor therapy. ..
  10. pmc High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma
    Aaron M Udager
    Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan
    Cancer Res 75:2600-6. 2015
    ..These findings implicate a prominent role for activating EGFR mutations in the pathogenesis of ISP and associated SNSCC and rationalize consideration of irreversible EGFR inhibitors in the therapy of these tumors...
  11. pmc Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer
    Kevin P Conlon
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109
    Mol Cell Proteomics 12:2714-23. 2013
    ..Our studies highlight the utility of fusion peptides as cancer biomarkers and carry broad implications for the use of protein biomarkers in cancer detection and monitoring. ..
  12. doi request reprint Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms
    Jennifer M Hummel
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 2200, USA
    Diagn Mol Pathol 21:176-83. 2012
    ..The implications for diagnosis and treatment of patients with concomitant BCR-ABL1 and JAK2(V617F) are discussed as well as how the BCR-ABL1 and JAK2(V617F)-positive clones may be related to one another...
  13. doi request reprint The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
    Megan S Lim
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Blood 114:1585-95. 2009
    ..Our studies carry important implications for the use of MS-driven approaches for the elucidation of neoplastic pathobiology, the identification of novel diagnostic biomarkers, and pathogenetically relevant therapeutic targets...